Fulgent Genetics (FLGT) Expected to Post Earnings on Thursday

Fulgent Genetics (NASDAQ:FLGT) is expected to be releasing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.65) per share and revenue of $86.30 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Fulgent Genetics Stock Up 0.4%

Shares of Fulgent Genetics stock opened at $19.37 on Wednesday. Fulgent Genetics has a one year low of $13.46 and a one year high of $31.04. The business has a 50-day simple moving average of $20.76 and a 200 day simple moving average of $19.42.

Insider Transactions at Fulgent Genetics

In related news, insider Hanlin Gao sold 1,673 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.66, for a total value of $32,891.18. Following the completion of the sale, the insider owned 986,117 shares in the company, valued at $19,387,060.22. The trade was a 0.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jian Xie sold 2,127 shares of Fulgent Genetics stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.66, for a total transaction of $41,816.82. Following the completion of the transaction, the chief operating officer owned 359,924 shares in the company, valued at approximately $7,076,105.84. The trade was a 0.59% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 5,932 shares of company stock worth $117,156. 36.18% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on FLGT shares. Weiss Ratings raised shares of Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. Wall Street Zen upgraded shares of Fulgent Genetics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. Finally, Piper Sandler lifted their price objective on Fulgent Genetics from $15.00 to $19.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Fulgent Genetics currently has a consensus rating of “Hold” and an average price target of $27.50.

About Fulgent Genetics

Fulgent Genetics, Inc is a technology-driven clinical diagnostics company that develops and performs genetic testing. Its testing platform uses next-generation sequencing and other molecular technologies to analyze DNA and support the diagnosis, screening and management of inherited and acquired diseases.

The company offers a range of tests, including panels for hereditary cancer, reproductive health and inherited disorders, as well as tumor profiling and other specialized clinical testing services.